Direct-to-consumer telehealth psychiatry has had a remarkable five-year run. Hims & Hers built a public company largely on the back of cash-pay prescribing of generic SSRIs and benzodiazepine alternatives. Talkspace converted from a flailing therapy app into a profitable enterprise mental health vendor. The category is up, broadly. The question is whether the next five years look anything like the last five.
Two structural shifts are now converging in a way that compresses the cash-pay telehealth model from both sides.
The supply side: DEA telehealth prescribing rules
The COVID-era telehealth flexibilities for controlled substance prescribing — the regulatory infrastructure that allowed Cerebral, Done, and others to scale ADHD stimulant prescribing — are now substantially curtailed. The DEA’s final rules require in-person evaluation for most controlled substance prescribing within a defined window, with exceptions that are narrower than the industry had lobbied for.
For psychiatric telehealth platforms, the immediate operational cost is real but not existential. Most psychiatric prescribing is not controlled-substance prescribing. SSRIs, SNRIs, atypicals, and most mood stabilizers are unaffected. But the platforms that built specifically around ADHD or anxiolytic prescribing — and the diagnostic patterns those drove — now have to either build in-person infrastructure or shrink their prescribing scope.
The demand side: insurance is catching up
The other compressing force is reimbursement. Major commercial payers have, over the past 18 months, materially expanded coverage of telehealth psychiatry. Aetna, UnitedHealth, and Anthem have all expanded their networks of contracted telepsychiatry providers. Headway and Alma — both insurance-credentialed marketplaces — have grown rapidly on this trend.
This is the bigger threat to the cash-pay model. The proposition that you would pay $99 for a Hims visit when your insurance now covers a Headway visit at a $20 copay relies on convenience differentials that are eroding. Hims’ counter-argument — that the cash-pay experience remains better, faster, and more discreet — is real but increasingly narrow.
What to watch
For Hims specifically, the diversification into weight loss (GLP-1 compounding) and sexual health has masked some of the pressure in mental health. The mental health vertical disclosures in the next two quarters of filings will tell whether the cash-pay psychiatric margin is holding.
For Talkspace, the enterprise pivot continues to look like the right strategic move. The B2B contract pipeline is the leading indicator.
For Teladoc, BetterHelp’s recent shrinkage is a structural issue, not a cyclical one. The category that BetterHelp pioneered — cash-pay therapy on demand — faces the same insurance-displacement pressure as cash-pay psychiatry, with even thinner unit economics.
The companies that benefit from this shift are not on most investors’ radar. Headway, Alma, and the insurance-credentialed marketplaces are private. The closest public proxy is the behavioral health services chains (Acadia, UHS) — beneficiaries by adjacency rather than by category.